MBRX Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Moleculin Biotech Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerMBRX

Market Cap14.4M

Cash RunwayRunway < 6 months

Next Catalyst2027-12-27

Public Research Snapshot

Moleculin Biotech Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Biospecimen Collection in Glioblastoma, IDH-Wildtype | MGMT-Unmethylated Glioblastoma (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
MB-107	n/a	n/a	Pivotal	Public pipeline row
Innovative Therapies	n/a	n/a	Pivotal	Public pipeline row
WP1066	Brain Tumor \| Medulloblastoma \| Brain Metastases	n/a	Phase 1	Public pipeline row
Liposomal Annamycin	Leukemia, Myeloid, Acute	n/a	Phase 1 \| Phase 2	Public pipeline row
Liposomal Annamycin (L-Annamycin)	Sarcoma,Soft Tissue \| Pulmonary Metastasis	n/a	Phase 1 \| Phase 2	Public pipeline row
Biospecimen Collection	Glioblastoma, IDH-Wildtype \| MGMT-Unmethylated Glioblastoma	n/a	Phase 2	Public pipeline row
WP1220	Cutaneous T-Cell Lymphoma/Mycosis Fungoides	n/a	Phase 1	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-12-27	Biospecimen Collection	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT04702503	Phase 1	COMPLETED	5	2019-11-15
NCT04887298	Phase 1 \| Phase 2	COMPLETED	36	2022-09-29
NCT04334863	Phase 1	COMPLETED	10	2023-02-03
NCT05319587	Phase 1 \| Phase 2	COMPLETED	22	2023-08-02
NCT05879250	Phase 2	RECRUITING	39	2027-12-27

Scientific Context

asset_name | Biospecimen Collection
catalyst_date_estimated | 2027-12-27
catalyst_type | Clinical Trial Completion
clinical_stage | Phase 2
clinical_stage | Phase 2

Want the full MBRX research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.